“The Phoundry team had no financial expertise or support to help start-up and enable the company to progress its operations. Hemera was hired based on a strong recommendation from Pappas Ventures and has served as our entire financial back-office. Hemera set up, enabled, and ran our entire financial infrastructure (processes, bookkeeping, forecasting, etc.). I found Ray (Hemera) to be timely in the delivery of his services, knowledgeable on all finance matters (and if he did not know something he knew who we needed to engage), and incredibly straightforward and easy to work with. I have been extremely pleased in our choice to work with Hemera. They get my highest recommendation.”
Paul Feldman, PhD
Chief Executive Officer, Co-Founder
Phoundry Pharmaceuticals, Inc. was founded in 2015 by six scientists who have industry-leading peptide expertise coupled with a significant amount of data, equipment, reagents, and consumables assigned by GlaxoSmithKline to serve as the basis for the company. Phoundry has created a portfolio of optimized peptides in various therapeutic categories, most notably diabetes and obesity. Phoundry, with the assistance of Hemera Financial Solutions, was acquired by Intarcia Therapeutics, Inc., a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology.